[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Houben
J J
JJ
Liem
B
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002074:Butanones / Q000145:classification*; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D015986:Confounding Factors, Epidemiologic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D000077239:Meloxicam; D000077430:Nabumetone; D011720:Pyrazoles; D013272:Stomach Diseases / Q000139:chemically induced* / Q000191:economics / Q000517:prevention & control*; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones; D013843:Thiazines / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D013843:Thiazines; D013844:Thiazoles; C116926:rofecoxib; D000068579:Celecoxib; D000077430:Nabumetone; D000077239:Meloxicam
Effectiviteit, veiligheid en kosten van strategieën ter preventie van gastropathie door gebruik van niet-steroïde anti-inflammatoire geneesmiddelen.